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Abstract: Opioid analgesics are essential in the treatment of moderate to severe cancer-related 
pain. Opioids are also recognized as important in the management of other severe, persistent 
refractory painful conditions, such as sickle cell disease and arthritis. In the clinical practice 
of pain management, stable opioid dosing generally depends on achieving maximal analgesia 
with tolerable side effects typical of opioid analgesics. There is a wide interindividual vari-
ability of responsiveness to exogenous opioids both in terms of analgesic efﬁ  cacy and side 
effects. Optimizing pain management for the individual patient may require sequential trials 
of opioid medications until the regimen with the most favorable therapeutic ratio of efﬁ  cacy 
to side effects is determined.
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Hydromorphone, a semi-synthetic opioid, is one of a family of closely related μ-agonist 
opioid drugs with dose-dependent analgesic properties. Hydromorphone has been used 
clinically to treat pain since the 1920s, and is commercially available in the United 
States in oral, rectal and injectible formulations.
A new formulation of extended release hydromorphone utilizing the OROS® tech-
nology has been demonstrated to provide sustained analgesia in patients with various 
types of chronic painful conditions. This new formulation may be advantageous to 
patients who tolerate hydromorphone well and other opioids poorly.
Opioid analgesics are essential in the treatment of moderate to severe cancer-related 
pain.1–3 Opioids are also recognized as important in the management of other severe, 
persistent refractory painful conditions, such as sickle cell disease and arthritis.4−11 In 
the clinical practice of pain management, stable opioid dosing generally depends on 
achieving maximal analgesia with tolerable side effects typical of opioid analgesics.3 
It is well known that there is a wide interindividual variability of responsiveness to 
exogenous opioids both in terms of analgesic efﬁ  cacy and side effects. Optimizing 
pain management for the individual patient may require sequential trials of opioid 
medications until the regimen with the most favorable therapeutic ratio of efﬁ  cacy to 
side effects is determined.
Hydromorphone
Hydromorphone, a semi-synthetic opioid, is one of a family of closely related μ-agonist 
opioid drugs with dose-dependent analgesic properties (Figure 1). Hydromorphone 
has been used clinically to treat pain since the 1920s,12 and is commercially available 
in the United States in oral, rectal and injectible formulations. Similar to other opioid 
agonists, hydromorphone does not have a ceiling effect for analgesia,3 and doses can be 
increased as needed to relieve moderate to severe pain. The relatively short duration of 
action of oral hydromorphone limits its use for persistent daily pain. Around-the-clock Therapeutics and Clinical Risk Management 2009:5 76
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dosing every 4 to 6 hours is often necessary to maintain 
adequate analgesia with immediate release oral preparations 
that have a relatively short duration of analgesic action.13,14 
For the treatment of acute post-operative pain, parenteral 
dosing intervals may be as short as every ten minutes using 
patient controlled analgesia devices. In the setting of short 
term acute pain management, parenteral opioids such as 
hydromorphone are advantageous for rapid titration to anal-
gesia and downward dose tapering as pain improves.
Hydromorphone has been used to treat acute and chronic 
pain in adults and children. It is routinely administered via the 
oral, rectal, intravenous, subcutaneous and spinal (epidural 
and intrathecal) routes. In studies of subcutaneous hydromor-
phone implants, it was demonstrated that drug was steadily 
released for weeks in vitro and in vivo, producing plasma 
levels comparable to subcutaneous infusion.15 There is no 
evidence that the abuse potential of hydromorphone differs 
from that of other opioids.16–18
There are several considerations in the choice of an initial 
opioid agonist medication and dosing schedule, including 
the personal history of efﬁ  cacy and tolerability of differ-
ent opioid analgesic medications.19 Prescribers should be 
familiar with the pharmacokinetics and pharmacokinetics of 
opioid analgesics. Patients with chronic painful conditions 
are usually best managed with a combination of sustained 
action and immediate release form of the same opioid drug, 
for control of “background” and “breakthrough” pain. 
Clinical pain management guidelines include procedures 
for converting from one route of drug administration to 
another and from one opioid analgesic agent to another. 
When converting hydromorphone from the parenteral to oral 
route one should use the potency ratio of 1.5:7.5 (conver-
sion factor of 5). Oral and rectal routes of administration are 
considered equipotent for the purpose of opioid conversions. 
The intravenous, subcutaneous and intramuscular routes are 
considered equipotent.20,21
Although hydromorphone may confer some advantages, 
caution should be used when prescribing for patients with 
renal insufﬁ  ciency, as there is a potential for toxicity due to 
accumulation of glucuronidated by-products.22,23
Published guidelines also include methods for calculating 
equianalgesic doses of the different opioid agonist 
drugs.3,13,19,24,25,26 For an initial opioid conversion, the use 
of a conservative dose is an appropriate strategy. Because 
of incomplete cross-tolerance among opioids,27 it is 
recommended that initial doses be reduced to 50%–75% 
of the calculated equianalgesic dose. After the initial 
conversion, upward dose titration is usually necessary to 
attain an adequate analgesic response.19,22,26,28 The data for the 
analgesic potency of hydromorphone compared to morphine 
are summarized in Table 1.
Single-dose comparison studies are an accepted method 
of establishing relative analgesic efﬁ  cacy and potency, as well 
as onset, peak, and duration of analgesic effects.29,30 A well-
controlled relative potency study of parenteral morphine and 
hydromorphone in patients with postoperative pain resulted 
in ratios of 8.3–11.1:1 (morphine signiﬁ  cantly less potent 
than hydromorphone).31 The ﬁ  rst study of the equianalgesic 
dose of morphine and hydromorphone in patients with cancer 
pain demonstrated an equivalence of parenteral morphine 
to hydromorphone of 7.9:1.32 Single-dose relative potency 
studies showed that oral morphine is 1/6 as potent as intra-
muscular (IM) morphine,33 that 10 mg of IM morphine 
is equianalgesic to 1.3 mg of IM hydromorphone,19 and 
that IM hydromorphone is 5 times more potent than oral 
hydromorphone, suggesting that 60 mg of oral morphine 
and 7.5 mg of oral hydromorphone are approximately 
equianalgesic. These results indicate a conversion ratio of 
8:1 (morphine:hydromorphone) for the oral formulations. 
In a repeated-dose study in patients with cancer-related pain, 
controlled-release hydromorphone and controlled-release 
morphine administered every 12 hours provided equivalent 
analgesia at a conversion ratio of 7.5:1.34
In two controlled clinical studies of 344 patients 
that compared the efficacy and safety of hydromor-
phone hydrochloride extended-release capsules with 
hydromorphone hydrochloride immediate-release tablets in 
the treatment of persistent moderate to severe pain (cancer 
and noncancer related), a conversion ratio of 8:1 mg of oral 
morphine to oral hydromorphone was used.13,31,35
In a retrospective clinical study comparing hydro-
morphone to morphine potencies, the authors observed a 
Figure 1 Chemical structure of hydromorphone.
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range of 3.7–5:1 (morphine to hydromorphone) depending 
on the direction of conversion, but independent of initial 
dose level.28
Additional studies have indicated that the conversion 
ratios may depend on the direction of conversion, that is, 
to or away from hydromorphone as summarized in Table 1. 
It is clear that hydromorphone is signiﬁ  cantly more potent 
than morphine on a milligram for milligram basis, regardless 
of the conversion direction or route of administration.
It cannot be overemphasized that conversion ratios 
are meant as an initial approximation and that individual 
clinical circumstances inﬂ  uence the calculation of an opioid 
dose.4,13,19,26 Close monitoring of patients is generally recom-
mended during further titration after the initial conversion 
from one opioid agonist to another.
Hydromorphone yields metabolites, especially the 
hydromorphone-3-glucuronide, that may contribute to 
excitotoxic neurologic states. With high dose administration, 
myoclonus and seizures may occur. The rare syndrome of 
hyperalgesia may manifest initially as worsening intensity 
of the pain syndrome and new, discrete allodynia in the 
saddle region (the author has observed this with high dose 
intrathecal administration). If these symptoms emerge, 
patients may respond to opioid rotation, dose reduction and 
administration of benzodiazepine.36,37,38
Modiﬁ  ed-, controlled-, sustained- or extended-release 
formulations of opioids have been in clinical use for 
over 25 years. Such formulations of hydromorphone 
hydrochloride have been developed to provide sustained 
analgesia for patients requiring medication for the control 
of persistent daily pain. Consistent pharmacokinetics and 
pharmacodynamics have been demonstrated with formula-
tions designed for every 12- and every 24-hour dosing in 
patients with cancer and noncancer related pain.35,39–46
Palladone™, a 24-hour hydromorphone product, was 
voluntarily withdrawn from the United States market by the 
manufacturer due to the potential for “dose dumping” when 
it was ingested simultaneously with alcohol, although no 
such adverse events were reported to have occurred during 
post-marketing surveillance.47,48
In summary, hydromorphone is a safe and effective opioid 
agonist analgesic for the management of acute and chronic 
pain of various etiologies in patients of all ages.
OROS® hydromorphone
OROS® is a patented technology for the osmotic-controlled 
release oral delivery of medication. OROS® has been 
reported to produce stable drug concentrations, uniform 
drug effects, reduced dosing frequency and an improved 
safety proﬁ  le. A review of the technology development over 
Table 1 Relative analgesic potency of hydromorphone compared to morphine
Reference Potency ratio Comments
Bruera42 3.6:1 Converting oral hydromorphone to morphine
Lawlor et ala,28
Mercandante61
3.7:1 Converting oral hydromorphone to morphine
Lawlor et ala,28 4.3:1 Average
Lawlor et ala,28
Mercandante61
5:1 Converting oral morphine to hydromorphone
Bruera42 5.3:1 Oral morphine to hydromorphone
Grilo62 5.7:1 Oral morphine to hydromorphone
Wirz63 5:1 Oral morphine to hydromorphone
Lee35 7.7:1 Oral morphine to hydromorphone
Wallace64 5:1 Oral morphine to hydromorphone
Dunbar65 3:1 Comparing intravenous use via patient controlled analgesia
Rapp66 5:1 Intravenous patient controlled analgesia
Coda67 5:1 Intravenous patient controlled analgesia
Collins68 5.1:1 Pediatric; intravenous patient controlled analgesia
Miller69 5:1 Subcutaneous at end of life
Hill70 10:1 Intravenous morphine to hydromorphone
Mahler31 8.3–11.1:1 Intravenous morphine to hydromorphone
Weinstein45 8:1 Synthesis of previously published data applied in clinical trial of oral once-daily hydromorphone
aData from oral and subcutaneous routes mixed.Therapeutics and Clinical Risk Management 2009:5 78
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the past 30 years has indicated that there are four different 
systems: the elementary osmotic pump, the two-layer osmotic 
push-pull tablet, the advanced longitudinally compressed 
tablet multilayer formulation, and the L-OROS™ system. 
These systems have been applied in several different 
therapeutic areas.49 According to the manufacturer, OROS® 
technology employs osmosis to provide precise, controlled 
drug delivery for up to 24 hours, can be used with a range 
of compounds, and may enhance bioavailability due to 
more efﬁ  cient drug absorption. There are currently thirteen 
OROS® commercial products available worldwide.50 In 2006, 
Jurnista™, a hydromorphone formulation utilizing the OROS® 
Push-Pull delivery system, was released in Europe after 
completing the European Mutual Recognition Program. Four 
dosage strengths will be available – 8, 16, 32 and 64 mg – for 
once-daily (every 24 hours) dosing.51
Two studies of OROS® hydromorphone formulations 
have been recently reported. In one study, the pharmaco-
kinetics of intravenous, oral immediate-release and oral 
extended-release (OROS®) formulations were compared. 
The OROS® formulation produced continuous release 
of medication over 24 hours, predicted to allow once 
daily dosing. The authors concluded that the formulation 
will produce less ﬂ  uctuation in plasma concentrations 
compared with repeated immediate-release equivalent 
dosing and that the formulation should therefore provide 
more consistent analgesic effect. The OROS® formulation 
was noted to have greater bioavailability, possibly related 
to decreased ﬁ  rst-pass effect or enterohepatic recycling 
of drug.52
An open-label, repeated-dose, single-treatment study 
evaluated the outcomes associated with standardized 
conversion from prior opioid therapy to the OROS® 
hydromorphone in patients with chronic malignant or 
nonmalignant pain. Eligibility criteria included baseline 
oral morphine equivalent requirement of greater than or 
equal to 45 mg daily. Over 400 patients received study drug. 
Signiﬁ  cant improvements in pain were noted with OROS® 
hydromorphone compared to prestudy medications. Adverse 
events were consistent with those expected, ie, side effects 
affecting primarily the gastrointestinal and central nervous 
systems.53
Several studies have supported the safety and efﬁ  cacy of 
this formulation in the treatment of cancer related and other 
acute and chronic painful conditions.54–58
A recent report revealed that when ingested with alcohol, 
dissolution of OROS® hydromorphone was not signiﬁ  cantly 
altered, ie, there was no “dose dumping.”59
Conclusion
With extended-release hydromorphone formulations 
available, those patients who tolerate hydromorphone far 
better than other opioids will be able to be treated with single 
agent opioid pharmacotherapy in a safe and convenient 
manner. Further research will be needed to establish the 
cost-effectiveness and advantages of long term treatment with 
extended-release hydromorphone preparations, particularly 
the OROS® formulation. One German study anticipated 
cost-effectiveness of this formulation for the treatment of 
pain associated with osteoarthritis.60
Given the prevalence of chronic painful conditions; the 
wide interindividual variability in responsiveness to opioids; 
and our aging population that will have an increasing need 
for safe and effective analgesics; broader clinical applications 
of new extended-release preparations of opioids can be 
anticipated. The OROS® hydromorphone will likely ﬁ  nd 
a therapeutic niche in the treatment of those patients with 
chronic painful conditions who have a more favorable 
therapeutic response to hydromorphone compared to other 
opioids. Clinical practitioners are encouraged to familiarize 
themselves with the pharmacology of opioids and to follow 
established guidelines for the management of pain that 
emphasize individualized treatment for optimal therapeutic 
outcomes.
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